Alembic Pharmaceuticals rises on getting USFDA’s nod for generic Nitrofurantoin capsules

02 Jul 2021 Evaluate

Alembic Pharmaceuticals is currently trading at Rs. 985.05, up by 3.60 points or 0.37% from its previous closing of Rs. 981.45 on the BSE.

The scrip opened at Rs. 989.85 and has touched a high and low of Rs. 1013.00 and Rs. 982.00 respectively. So far 17006 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1150.00 on 18-Dec-2020 and a 52 week low of Rs. 863.55 on 19-Mar-2021.

Last one week high and low of the scrip stood at Rs. 1013.00 and Rs. 974.95 respectively. The current market cap of the company is Rs. 19349.67 crore.

The promoters holding in the company stood at 69.48%, while Institutions and Non-Institutions held 17.53% and 12.99% respectively.

Alembic Pharmaceuticals has received approval from the US health regulator for its generic Nitrofurantoin capsules indicated for the treatment of urinary tract infections. The company has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Nitrofurantoin capsules, USP in the strengths of 25 mg, 50 mg and 100 mg.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

835.30 -7.85 (-0.93%)
30-Dec-2025 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.80
Dr. Reddys Lab 1265.95
Cipla 1491.40
Zydus Lifesciences 902.30
Lupin 2081.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×